亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

無錫中坤生化科技有限公司  

醫藥中間體,OLED中間體

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:宋美霞
  • 電話:0510-66893528 ,0510-85629785
  • 郵件:wxzksmx@163.com
  • 傳真:0510-85625359
  • QQ:1811737643
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 1-溴-3-甲基金剛烷
1-溴-3-甲基金剛烷
單價 面議對比
詢價 暫無
發貨 江蘇無錫市付款后3天內
型號 702-77-2
過期 長期有效
更新 2013-09-27 10:42
 
詳細信息

中文名稱: 1-溴-3-甲基金剛烷*******.chemicalbook.*/ChemicalProductProperty_CN_CB1703450.htm
中文同義詞:
英文名稱: 1-BROMO-3-METHYLADAMANTANE
英文同義詞: 1-BROMO-3-METHYLADAMANTANE;1-BroMo-3-Methyl-tricyclo[3.3.1.13,7]decane;1-Methyl-3-broMoadaMantane;NSC 255329
CAS號: 702-77-2
分子式: C11H17Br
分子量: 229.16
EINECS號:
相關類別: Adamantane derivatives;Intermediates & Fine Chemicals;Pharmaceuticals

©2025 無錫中坤生化科技有限公司 版權所有   技術支持:化工網   訪問量:4886  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |